Sgd Pharma, headquartered in France, is a leading player in the pharmaceutical packaging industry, specialising in the design and manufacture of glass primary packaging solutions. Founded in 2002, the company has established a strong presence across Europe, Asia, and the Americas, catering to the diverse needs of the pharmaceutical and biotechnology sectors.
With a commitment to quality and innovation, Sgd Pharma offers a comprehensive range of products, including vials, ampoules, and syringes, all designed to meet stringent regulatory standards. Their unique approach combines advanced manufacturing techniques with a focus on sustainability, positioning them as a trusted partner for global pharmaceutical companies. Notably, Sgd Pharma has achieved significant milestones in product development and market expansion, solidifying its reputation as a key player in the industry.
+3 vs industry average
Sgd Pharma’s score of 24 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sgd Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Rubber and Plastic Products has above-average carbon intensity
Industry performance
The Rubber and Plastic Products industry has reduced its overall emissions by 30% since 2019
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Sgd Pharma's reported carbon emissions
In 2024, SGD Pharma reported total carbon emissions of approximately 181,487,000 kg CO2e, comprising 121,578,000 kg CO2e from Scope 1 and 59,909,000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 emissions by 42% by 2030 compared to 2022 levels, aligning with the 1.5°C climate threshold. Additionally, SGD Pharma plans to achieve a 35% reduction in CO2 emissions by 2030 and a 65% reduction by 2040, using 2020 as a baseline for its plants in France, Germany, India, and China. SGD Pharma is committed to achieving carbon neutrality by 2050, reflecting its long-term climate strategy. The company has not disclosed Scope 3 emissions data, indicating a focus on direct and indirect emissions from its operations. These initiatives demonstrate SGD Pharma's proactive approach to addressing climate change and its commitment to sustainable practices within the pharmaceutical packaging industry.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Sgd Pharma’s Climate Goals (2030 & 2050)
6 goals2040
65% reduction in all scopes
Looking ahead, SGD Pharma is targeting a 65% reduction in CO2 emissions by 2040 and will continue to work to increase this number.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 6 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Sgd Pharma
Frequently asked questions
Common questions about Sgd Pharma’s sustainability data and climate commitments
Data year: 2024
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project